Anavex Life Sciences (AVXL) Receivables Refunds (2011 - 2025)
Anavex Life Sciences recorded quarterly Receivables Refunds of $844000.0 in Q4 2025, up 4.33% quarter-over-quarter from $809000.0 in Q3 2025, and down 66.99% year-over-year from $2.6 million in Q4 2024.
Anavex Life Sciences' Receivables Refunds history runs 10 years deep, the most recent figure standing at $844000.0 for Q4 2025.
- In Q4 2025, Receivables Refunds fell 66.99% year-over-year to $844000.0; the TTM figure through Dec 2025 stood at $844000.0 (down 66.99% YoY), while the FY2025 annual figure was $809000.0, down 66.97% from the prior year.
- Receivables Refunds came in at $844000.0 for Q4 2025 at Anavex Life Sciences, up from $809000.0 in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $9.1 million in Q3 2021 to a low of $666000.0 in Q1 2025.
- A 5-year average of $3.9 million and a median of $3.4 million in 2022 frame the typical range for Receivables Refunds.
- Across the five-year window, Receivables Refunds jumped 142.43% in 2021 and sank 82.4% in 2025, its largest moves.
- Anavex Life Sciences' Receivables Refunds stood at $5.4 million in 2021, then slipped by 23.78% to $4.1 million in 2022, then retreated by 13.32% to $3.5 million in 2023, then dropped by 27.95% to $2.6 million in 2024, then plunged by 66.99% to $844000.0 in 2025.
- According to Business Quant data, Receivables Refunds over the past three periods registered $844000.0, $809000.0, and $820000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Refund Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 844,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 844,000.00 |
| Sep 30, 2025 | 809,000.00 |
| Jun 30, 2025 | 820,000.00 |
| Mar 31, 2025 | 666,000.00 |
| Dec 31, 2024 | 2.56 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | 3.79 Mn |
| Dec 31, 2023 | 3.55 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Jun 30, 2023 | 2.17 Mn |
| Mar 31, 2023 | 4.74 Mn |
| Dec 31, 2022 | 4.09 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | 6.56 Mn |
| Mar 31, 2022 | 6.47 Mn |
| Dec 31, 2021 | 5.37 Mn |
| Sep 30, 2021 | 9.14 Mn |
| Jun 30, 2021 | 8.60 Mn |
| Mar 31, 2021 | 7.33 Mn |
| Dec 31, 2020 | 6.58 Mn |
| Sep 30, 2020 | 4.85 Mn |
| Jun 30, 2020 | 3.55 Mn |
| Mar 31, 2020 | 4.15 Mn |
| Dec 31, 2019 | 3.73 Mn |
| Sep 30, 2019 | 2.64 Mn |
| Sep 30, 2018 | 1.87 Mn |
| Mar 31, 2012 | 953.00 |
| Sep 30, 2011 | 809.00 |